FRESH-PEF96-en
MELISSE
| Name | Country code |
|---|---|
| France | fr |
['Clinical data']
Individuals
| Topic | Vocabulary |
|---|---|
| Oncology | health theme |
| Healthcare system determinants: Use of care | health determinant |
| Healthcare system determinants | health determinant |
{"level_sex_clusion_I":[{"value":"Male","concept":{"vocab":"MeSH","vocabURI":"D008297"}},{"value":"Female","concept":{"vocab":"MeSH","vocabURI":"D005260"}}],"level_age_clusion_I":[{"value":"Young Adult (19 to 24 years)","concept":{"vocab":"MeSH","vocabURI":"D055815"}},{"value":"Adult (25 to 44 years)","concept":{"vocab":"MeSH","vocabURI":"D000328"}},{"value":"Middle Aged (45 to 64 years)","concept":{"vocab":"MeSH","vocabURI":"D008875"}},{"value":"Aged (65 to 79 years)","concept":{"vocab":"MeSH","vocabURI":"D000368"}},{"value":"Aged, 80 and over (80 years and more)","concept":{"vocab":"MeSH","vocabURI":"D000369"}}],"level_type_clusion_I":"General population","level_type_clusion_other":"","clusion_I":"Adult patient with introduction to thalidomide or lenalidomide treatment for multiple myeloma (1st, 2nd or 3rd line of chemotherapy). ","clusion_E":"patient participating or having participated over the previous three months in a biomedical trial on anticoagulants"}
| Name |
|---|
| Anne;LAMBLIN |
| Name | Role |
|---|---|
| LABORATOIRES LEO (LEO PHARMA) | sponsor |
| Name |
|---|
| AGENCE NATIONALE DE RECHERCHES SUR LE SIDA ET LES HEPATITES VIRALES (ANRS MIE) |
| Agency name |
|---|
| CNIL |
| CPP |
['Through organizations (health services or institutions, schools, businesses, etc.)']
['{"concept":{"vocabURI":"Other","vocab":"CESSDA"},"value":"Other"}']
Access on specific project only
Observational Study
| Start | End |
|---|---|
| 2008-01-01 | 2011-01-01 |
{"value":"Restricted access","extLink":[{"title":"COAR","uri":"http://purl.org/coar/access_right/c_16ec"}]}
| Name | |
|---|---|
| Anne;LAMBLIN | anne.lamblin@leo-pharma.com |